🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tremendously proud to share my fellowship work, online today in Nature Medicine. We tried to understand why CAR T therapy for AML doesn't work as well as we hoped it would, and how we can solve that. 👇🧵1/10 Penn Medicine CHOP Research Saar Gill nature.com/articles/s4159…

Welcome Dr. Collins!

Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at NatureGen! 🎉🎈🍾 nature.com/articles/s4158…

The UPENN Leukemia Program is recruiting clinicians for the 2025 academic year in Philadelphia. The leukemia team consists of a group of global leaders in their fields with track records for successful mentorship. If interested please apply at apply.interfolio.com/157257

Forever thankful to the Cancer Discovery team and Elizabeth McKenna ! CU Anschutz Division of Hematology CU Anschutz Cancer Biology Graduate Program CU Department of Medicine CU MSTP

Celebrating Kim's appointment to the National Cancer Advisory Board by the POTUS! Congrats to our fearless leader! Press release from the white house: whitehouse.gov/briefing-room/…

Our manuscript refining risk prediction for HMA+venetoclax-based treatment in AML is now out in @BloodJournal first edition! ashpublications.org/blood/article/…

This paper changes everything in the AML field. This is the best model of the most frequent and aggressive acute myeloid leukemia. When we beat this disease, we will look back at this paper as marking the beginning of the end. @bowman_rl Ross Levine cell.com/cancer-cell/ab…

Excited to share our first story from the lab (and some good news!) led by the impressive Morgan Drucker @cincychildrens and Darren Lee @cincymedicine looking at clonal evolution in NPM1-mut AML at single cell resolution! 🧵/1 biorxiv.org/cgi/content/sh…

Looking to inspire the next generation of physician-scientists? The University of Colorado School of Medicine invites applications for Program Director for the NIH-funded Medical Scientist Training Program (MSTP) at the Anschutz Medical Campus. cu.taleo.net/careersection/…

CU Cancer Center member Mathew Angelos (Mat Angelos), MD, PhD, is pioneering CU Anschutz Medical Campus's first entirely home-grown chimeric antigen receptor (CAR) T-cell trial 👇 news.cuanschutz.edu/gates/early-ca…

The new approach for eradicating leukemic stem cells in blast phase chronic myeloid leukemiainvolves the combination of venetoclax and tyrosine kinase inhibitors. Read the new study by Minhajuddin and colleagues. haematologica.org/article/view/h…

Unbelievably excited for this next step in my career!

Match Day 2025 is here! 🎉 Meet the newest class of interns joining us for their residency at Stanford Department of Medicine: ✔️ 44 categorical internal medicine interns ✔️ 18 anesthesia & neurology interns Welcome to the #StanDOM Family! ❤️ #Match2025

Anagha Inguva Sheth, PhD So excited to welcome you to StanfordMedRes & Stanford Department of Medicine — you’re part of an absolutely incredible group of physician-scientists in next year’s intern class! 🙂🍾

Excited to share our preprint (manuscript in review): TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia. UCSF Helen Diller Family Comprehensive Cancer Ctr biorxiv.org/content/10.110…

A new KRG study led by Sumiko Takao et al Nature Communications uncovers how epigenetic mechanisms control human leukemia stem cells (LSCs) that fuel therapy resistance in AML. nature.com/articles/s4146… #Leukemia #Epigenetics

Author Ravi Majeti is featured in the Tumor Metabolism Collection. Read his article, IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation brnw.ch/21wSkjA Check out the full collection: brnw.ch/21wSkjB

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for an induction of an adaptive stress response - available online now at Leukemia! Thanks to all co-authors and funding support from ASH Conquer Cancer, the ASCO Foundation NIH nature.com/articles/s4137…

Search for novel strategies in TP53 AML reveals mevalonate pathway importance in chemoreststance. Congratulations to Sarah Skuli and team on this work!